The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Therapeutic targeting of “undruggable” MYC
Open accessAbstract
c-MYC controls global gene expression and regulates cell proliferation, cell differentiation, cell cycle, metabolism and apoptosis. According to some estimates, MYC is dysregulated in ≈70% of human cancers and strong evidence implicates aberrantly expressed MYC in both tumor initiation and maintenance. In vivo studies show that MYC inhibition elicits a prominent anti-proliferative effect and sustained tumor regression while any alteration on healthy tissue remains reversible. This opens an exploitable window for treatment that makes MYC one of the most appealing therapeutic targets for cancer drug development. This review describes the main functional and structural features of the protein structure of MYC and provides a general overview of the most relevant or recently identified interactors that modulate MYC oncogenic activity. This review also summarizes the different approaches aiming to abrogate MYC oncogenic function, with a particular focus on the prototype inhibitors designed for the direct and indirect targeting of MYC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Boija, A., Klein, I. A., Sabari, B. R., Dall’Agnese, A., Coffey, E. L., Zamudio, A. V., Li, C. H., Shrinivas, K., Manteiga, J. C., Hannett, N. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.042 · Cited by 1,815
Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Targeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins
McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D., & Cole, M. D. (1998) · Cell · doi:10.1016/s0092-8674(00)81479-8 · Cited by 693
Non-transcriptional control of DNA replication by c-Myc
Dominguez-Sola, D., Ying, C. Y., Grandori, C., Ruggiero, L., Chen, B., Li, M., Galloway, D. A., Gu, W., Gautier, J., & Dalla-Favera, R. (2007) · Nature · doi:10.1038/nature05953 · Cited by 651
Repression of p15INK4b expression by Myc through association with Miz-1
Staller, P., Peukert, K., Kiermaier, A., Seoane, J., Lukas, J., Karsunky, H., Möröy, T., Bartek, J., Massagué, J., Hänel, F., et al. (2001) · Nature Cell Biology · doi:10.1038/35070076 · Cited by 575
Oncogenic activity of the c-Myc protein requires dimerization with Max
Amati, B., Brooks, M. W., Levy, N., Littlewood, T. D., Evan, G. I., & Land, H. (1993) · Cell · doi:10.1016/0092-8674(93)90663-b · Cited by 560
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551
Roles of F-box proteins in cancer
Wang, Z., Liu, P., Inuzuka, H., & Wei, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3700 · Cited by 523
FBXW7: a critical tumor suppressor of human cancers
Yeh, C.-H., Bellon, M., & Nicot, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0857-2 · Cited by 515
MYC as a target for cancer treatment
Duffy, M. J., O'Grady, S., Tang, M., & Crown, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 514
Partitioning of cancer therapeutics in nuclear condensates
Klein, I. A., Boija, A., Afeyan, L. K., Hawken, S. W., Fan, M., Dall'Agnese, A., Oksuz, O., Henninger, J. E., Shrinivas, K., Sabari, B. R., et al. (2020) · Science · doi:10.1126/science.aaz4427 · Cited by 499
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Hsu, T. Y.-T., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015) · Nature · doi:10.1038/nature14985 · Cited by 492
Gregory, M. A., & Hann, S. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2423-2435.2000 · Cited by 469
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 465
Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463
Definition of regions in human c-myc that are involved in transformation and nuclear localization.
Stone, J., de Lange, T., Ramsay, G., Jakobovits, E., Bishop, J. M., Varmus, H., & Lee, W. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.5.1697 · Cited by 447
Myc represses transcription through recruitment of DNA methyltransferase corepressor
Brenner, C., Deplus, R., Didelot, C., Loriot, A., Viré, E., De Smet, C., Gutierrez, A., Danovi, D., Bernard, D., Boon, T., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600509 · Cited by 445
Skp2 Regulates Myc Protein Stability and Activity
Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E., & Tansey, W. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00173-4 · Cited by 440
An amino-terminal c-myc domain required for neoplastic transformation activates transcription.
Kato, G. J., Barrett, J., Villa-Garcia, M., & Dang, C. V. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5914 · Cited by 410
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K. I., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00193-x · Cited by 408
MYC recruits the TIP60 histone acetyltransferase complex to chromatin
Frank, S. R., Parisi, T., Taubert, S., Fernandez, P., Fuchs, M., Chan, H., Livingston, D. M., & Amati, B. (2003) · EMBO reports · doi:10.1038/sj.embor.embor861 · Cited by 405
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701953104 · Cited by 403
Adhikary, S., Marinoni, F., Hock, A., Hulleman, E., Popov, N., Beier, R., Bernard, S., Quarto, M., Capra, M., Goettig, S., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.016 · Cited by 403
c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function
Cheng, S.-W. G., Davies, K. P., Yung, E., Beltran, R. J., Yu, J., & Kalpana, G. V. (1999) · Nature Genetics · doi:10.1038/8811 · Cited by 396
Chan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391
Binding of myc proteins to canonical and noncanonical DNA sequences.
Blackwell, T. K., Huang, J., Ma, A., Kretzner, L., Alt, F. W., Eisenman, R. N., & Weintraub, H. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.9.5216 · Cited by 376
Zhang, L., Riley-Gillis, B., Vijay, P., & Shen, Y. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1129 · Cited by 365
BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
Devaiah, B. N., Case-Borden, C., Gegonne, A., Hsu, C. H., Chen, Q., Meerzaman, D., Dey, A., Ozato, K., & Singer, D. S. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3228 · Cited by 361
The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60
Patel, J. H., Du, Y., Ard, P. G., Phillips, C., Carella, B., Chen, C.-J., Rakowski, C., Chatterjee, C., Lieberman, P. M., Lane, W. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10826-10834.2004 · Cited by 354
Identification of the human c-myc protein nuclear translocation signal.
Dang, C. V., & Lee, W. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.10.4048 · Cited by 337
USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.-P., Prakash, S., et al. (2017) · Nature · doi:10.1038/nature24006 · Cited by 333
Conti, E., & Kuriyan, J. (2000) · Structure · doi:10.1016/s0969-2126(00)00107-6 · Cited by 307
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.005 · Cited by 299
Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R., & Magrath, I. (1993) · Nature Genetics · doi:10.1038/ng0993-56 · Cited by 285
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
Gustafson, W. C., Meyerowitz, J. G., Nekritz, E. A., Chen, J., Benes, C., Charron, E., Simonds, E. F., Seeger, R., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 278
Deregulated MYC expression induces dependence upon AMPK-related kinase 5
Liu, L., Ulbrich, J., Müller, J., Wüstefeld, T., Aeberhard, L., Kress, T. R., Muthalagu, N., Rycak, L., Rudalska, R., Moll, R., et al. (2012) · Nature · doi:10.1038/nature10927 · Cited by 276
Zippo, A., De Robertis, A., Serafini, R., & Oliviero, S. (2007) · Nature Cell Biology · doi:10.1038/ncb1618 · Cited by 273
Dauch, D., Rudalska, R., Cossa, G., Nault, J.-C., Kang, T.-W., Wuestefeld, T., Hohmeyer, A., Imbeaud, S., Yevsa, T., Hoenicke, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4107 · Cited by 273
Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272
Zhao, X., Heng, J. I.-T., Guardavaccaro, D., Jiang, R., Pagano, M., Guillemot, F., Iavarone, A., & Lasorella, A. (2008) · Nature Cell Biology · doi:10.1038/ncb1727 · Cited by 271
Pim kinase-dependent inhibition of c-Myc degradation
Zhang, Y., Wang, Z., Li, X., & Magnuson, N. S. (2008) · Oncogene · doi:10.1038/onc.2008.123 · Cited by 265
Alqahtani, A., Choucair, K., Ashraf, M., Hammouda, D. M., Alloghbi, A., Khan, T., Senzer, N., & Nemunaitis, J. (2019) · Future Science OA · doi:10.4155/fsoa-2018-0115 · Cited by 240
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma
Zeid, R., Lawlor, M. A., Poon, E., Reyes, J. M., Fulciniti, M., Lopez, M. A., Scott, T. G., Nabet, B., Erb, M. A., Winter, G. E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0044-9 · Cited by 230
Design and properties of a Myc derivative that efficiently homodimerizes
Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., & Nasi, S. (1998) · Oncogene · doi:10.1038/sj.onc.1202199 · Cited by 221
Faiola, F., Liu, X., Lo, S., Pan, S., Zhang, K., Lymar, E., Farina, A., & Martinez, E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10220-10234.2005 · Cited by 218
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Beaulieu, M.-E., Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Rahl, P., Maltais, L., Zacarias-Fluck, M. F., Casacuberta-Serra, S., Serrano del Pozo, E., Fiore, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5012 · Cited by 209
HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma
Tavana, O., Li, D., Dai, C., Lopez, G., Banerjee, D., Kon, N., Chen, C., Califano, A., Yamashiro, D. J., Sun, H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4180 · Cited by 202
Kalkat, M., Resetca, D., Lourenco, C., Chan, P.-K., Wei, Y., Shiah, Y.-J., Vitkin, N., Tong, Y., Sunnerhagen, M., Done, S. J., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.031 · Cited by 201
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
Annibali, D., Whitfield, J. R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzàlez-Juncà, A., Sodir, N. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5632 · Cited by 200
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
Mammalian MYC Proteins and Cancer
Tansey, W. P. (2014) · New Journal of Science · doi:10.1155/2014/757534 · Cited by 196
O’Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 190
Younes, A., Berdeja, J. G., Patel, M. R., Flinn, I., Gerecitano, J. F., Neelapu, S. S., Kelly, K. R., Copeland, A. R., Akins, A., Clancy, M. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00584-7 · Cited by 186
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors
Richards, M. W., Burgess, S. G., Poon, E., Carstensen, A., Eilers, M., Chesler, L., & Bayliss, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610626113 · Cited by 180
Selective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
Liu, X., Tesfai, J., Evrard, Y. A., Dent, S., & Martinez, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211795200 · Cited by 175
Xiao, D., Yue, M., Su, H., Ren, P., Jiang, J., Li, F., Hu, Y., Du, H., Liu, H., & Qing, G. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.016 · Cited by 175
Mechanism of transcriptional activation by the Myc oncoproteins
Cowling, V. H., & Cole, M. D. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.08.001 · Cited by 173
Prolyl isomerase Pin1: a promoter of cancer and a target for therapy
Chen, Y., Wu, Y., Yang, H., Li, X., Jie, M., Hu, C.-J., Wu, Y., Yang, S., & Yang, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0844-y · Cited by 173
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
Dubiella, C., Pinch, B. J., Koikawa, K., Zaidman, D., Poon, E., Manz, T. D., Nabet, B., He, S., Resnick, E., Rogel, A., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00786-7 · Cited by 173
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
MYC protein stability is negatively regulated by BRD4
Devaiah, B. N., Mu, J., Akman, B., Uppal, S., Weissman, J. D., Cheng, D., Baranello, L., Nie, Z., Levens, D., & Singer, D. S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919507117 · Cited by 165
O’Connor, O. A., Özcan, M., Jacobsen, E. D., Roncero, J. M., Trotman, J., Demeter, J., Masszi, T., Pereira, J. C., Ramchandren, R., Beaven, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00899 · Cited by 162
Inhibitor of MYC identified in a Kröhnke pyridine library
Hart, J. R., Garner, A. L., Yu, J., Ito, Y., Sun, M., Ueno, L. A., Rhee, J., Baksh, M. M., Stefan, E., Hartl, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319488111 · Cited by 159
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
Campaner, E., Rustighi, A., Zannini, A., Cristiani, A., Piazza, S., Ciani, Y., Kalid, O., Golan, G., Baloglu, E., Shacham, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15772 · Cited by 159
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 156
TRRAP-Dependent and TRRAP-Independent Transcriptional Activation by Myc Family Oncoproteins
Nikiforov, M. A., Chandriani, S. J., Park, J. H., Kotenko, I., Matheos, D. P., Johnsson, A., McMahon, S. B., & Cole, M. D. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5054-5063.2002 · Cited by 153
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Sun, K., Atoyan, R., Borek, M. A., DellaRocca, S., Samson, M., Ma, A. W., Xu, G.-X., Patterson, T. D., Tuck, D. P., Viner, J. L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0390 · Cited by 143
Myc and its interactors take shape
Tu, W. B., Helander, S., Pilstål, R., Hickman, K. A., Lourenco, C., Jurišica, I., Raught, B., Wallner, B., Sunnerhagen, M., & Penn, L. Z. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.06.002 · Cited by 142
PIM Kinase as an Executional Target in Cancer
Zhang, X., Song, M., Kundu, J. K., Lee, M., & Liu, Z. (2018) · Journal of Cancer Prevention · doi:10.15430/jcp.2018.23.3.109 · Cited by 141
Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis
Jiang, J., Wang, J., Yue, M., Cai, X., Wang, T., Wu, C., Su, H., Wang, Y., Han, M., Zhang, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.001 · Cited by 140
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 139
Sequence-Specific Transcriptional Activation by Myc and Repression by Max
Amin, C. S., Wagner, A. J., & Hay, N. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.383-390.1993 · Cited by 137
Oki, Y., Kelly, K. R., Flinn, I. W., Patel, M. R., Gharavi, R. B., Ma, A., Parker, J., Hafeez, A., Tuck, D. P., & Younes, A. (2017) · Haematologica · doi:10.3324/haematol.2017.172882 · Cited by 136
Myc-Mediated Transcriptional Repression by Recruitment of Histone Deacetylase
Kurland, J. F., & Tansey, W. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6552 · Cited by 135
Peter, S., Bultinck, J., Myant, K., Jaenicke, L. A., Walz, S., Müller, J., Gmachl, M., Treu, M., Boehmelt, G., Ade, C. P., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403927 · Cited by 131
Flinn, E. M., Busch, C. M. C., & Wright, A. P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5961 · Cited by 131
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
Felsher, D. W. (2010) · Genes & Cancer · doi:10.1177/1947601910377798 · Cited by 129
A conserved element in Myc that negatively regulates its proapoptotic activity
Herbst, A., Hemann, M. T., Tworkowski, K. A., Salghetti, S. E., Lowe, S. W., & Tansey, W. P. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400333 · Cited by 127
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer, N. J., Liu, X., Magin, R. S., Doherty, L. M., Chan, W. C., Ficarro, S. B., Hu, W., Roberts, R. M., Iacob, R. E., Stolte, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62076-x · Cited by 125
Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity
Aho, E. R., Wang, J., Gogliotti, R. D., Howard, G. C., Phan, J., Acharya, P., Macdonald, J. D., Cheng, K. C.-C., Lorey, S. L., Lu, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.047 · Cited by 124
Thomas, L. R., Adams, C. M., Wang, J., Weissmiller, A. M., Creighton, J. H., Lorey, S. L., Liu, Q., Fesik, S. W., Eischen, C. M., & Tansey, W. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910391116 · Cited by 124
Jaenicke, L. A., von Eyß, B., Carstensen, A., Wolf, E., Xu, W., Greifenberg, A. K., Geyer, M., Eilers, M., & Popov, N. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.007 · Cited by 123
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Massó-Vallés, D., Beaulieu, M.-È., & Soucek, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1723548 · Cited by 123
Löwenberg, B., Muus, P., Ossenkoppele, G. J., Rousselot, P. H., Cahn, J.-Y. Y., Ifrah, N., Martinelli, G., Amadori, S., Berman, E., Sonneveld, P., et al. (2011) · Blood · doi:10.1182/blood-2011-07-366930 · Cited by 121
Cortes, J., Tamura, K., DeAngelo, D. J., de Bono, J., Lorente, D., Minden, M., Uy, G. L., Kantarjian, H., Chen, L. S., Gandhi, V., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0082-1 · Cited by 120
Zhou, S., Zhang, S., Wang, L., Huang, S., Yuan, Y., Yang, J., Wang, H., Li, X., Wang, P., Zhou, L., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0218-z · Cited by 113
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
Luszczak, S., Kumar, C., Sathyadevan, V. K., Simpson, B. S., Gately, K. A., Whitaker, H. C., & Heavey, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0109-y · Cited by 102
Targeting MYCN in Pediatric and Adult Cancers
Liu, Z., Chen, S. S., Clarke, S., Veschi, V., & Thiele, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.623679 · Cited by 102
Huang, H., Weng, H., Wang, L., Yu, C.-H., Huang, Q.-J., Zhao, P., Wen, J.-Z., Zhou, H., & Qu, L. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0066 · Cited by 100
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
Foulks, J. M., Carpenter, K. J., LUO, B. H., Xu, Y., Senina, A. V., Nix, R. N., Chan, A., Clifford, A., Wilkes, M. M., Vollmer, D. L., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.05.004 · Cited by 99
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia
Jin, Q., Martinez, C. A., Arcipowski, K. M., Zhu, Y., Gutierrez-Diaz, B. T., Wang, K. K., Johnson, M. R., Volk, A. G., Wang, F., Wu, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1740 · Cited by 99
PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer
Kirschner, A. N., Wang, J., van der Meer, R., Anderson, P. D., Coronel, O. E. F., Kushner, M. H., Everett, J. H., Hameed, O. M., Keeton, E. K., Ahdesmaki, M. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju407 · Cited by 96
Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
Lin, C., Nasr, Z., Premsrirut, P. K., Porco, J. A. J., Hippo, Y., Lowe, S. W., & Pelletier, J. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.010 · Cited by 94
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
Demma, M. J., Mapelli, C., Sun, A., Bodea, S., Ruprecht, B., Javaid, S., Wiswell, D., Muise, E., Chen, S., Zelina, J., et al. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-19 · Cited by 92
Zhou, L. Q., Yu, X., Li, M., Gong, G., Liu, W., Tian, L., Zuo, H., Li, W., Gao, F., & Liu, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.031 · Cited by 92
Identification of a potent and selective covalent Pin1 inhibitor
Pinch, B. J., Doctor, Z. M., Nabet, B., Browne, C. M., Seo, H., Mohardt, M. L., Kozono, S., Lian, X., Manz, T. D., Chun, Y., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0550-9 · Cited by 92
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
Fiorentino, F. P., Tokgün, P. E., Solé‐Sánchez, S., Giampaolo, S., Tokgün, O., Jauset, T., Kohno, T., Perucho, M., Soucek, L., & Yokota, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8826 · Cited by 87
Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma
Zhang, Y., Zvi, Y. S., Batko, B. D., Zaphiros, N. H., O’Donnell, E. F., Wang, J., Satô, K., Yang, R., Geller, D. S., Koirala, P., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32428-9 · Cited by 82
Raab, M. S., Thomas, S. K., Ocio, E. M., Guenther, A., Goh, Y. T., Talpaz, M., Hohmann, N., Zhao, S., Xiang, F., Simon, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0482-0 · Cited by 82
Targeted Disruption of Myc–Max Oncoprotein Complex by a Small Molecule
Choi, S. H., Mahankali, M., Lee, S. J., Hull, M. V., Petrassi, H. M., Chatterjee, A. K., Schultz, P. G., Jones, K. A., & Shen, W. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00799 · Cited by 77
Dissecting transcriptional amplification by MYC
Nie, Z., Guo, C., Das, S., Chow, C. C., Batchelor, E., Simons, S. S., & Levens, D. (2020) · eLife · doi:10.7554/elife.52483 · Cited by 69
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response
Chatterjee, S., Chakraborty, P., Daenthanasanmak, A., Iamsawat, S., Andrejeva, G., Luevano, L. A., Wolf, M. M., Baliga, U. K., Krieg, C., Beeson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0706 · Cited by 68
Multiple direct interactions of TBP with the MYC oncoprotein
Wei, Y., Resetca, D., Li, Z., Johansson-Åkhe, I., Ahlner, A., Helander, S., Wallenhammar, A., Morad, V., Raught, B., Wallner, B., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0321-z · Cited by 68
Kato, F., Fiorentino, F. P., Alibés, A., Perucho, M., Sánchez‐Céspedes, M., Kohno, T., & Yokota, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12671 · Cited by 67
Macdonald, J. D., Chacón Simon, S., Han, C., Wang, F., Shaw, J. G., Howes, J. E., Sai, J., Yuh, J. P., Camper, D., Alicie, B. M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01411 · Cited by 66
Tohmé, R., Izadmehr, S., Gandhe, S., Tabaro, G., Vallabhaneni, S., Thomas, A., Vasireddi, N., Dhawan, N. S., Ma’ayan, A., Sharma, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125693 · Cited by 66
Sammak, S., Hamdani, N., Gorrec, F., Allen, M. D., Freund, S. M. V., Bycroft, M., & Zinzalla, G. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00296 · Cited by 65
Writing and erasing MYC ubiquitination and SUMOylation
Chen, Y., Sun, X., Sears, R. C., & Dai, M. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.05.006 · Cited by 65
Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function
Jiang, H., Bower, K. E., Beuscher, A. E., Zhou, B., Bobkov, A. A., Olson, A. J., & Vogt, P. K. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054858 · Cited by 62
Pre-Anchoring of Pin1 to Unphosphorylated c-Myc in a Fuzzy Complex Regulates c-Myc Activity
Helander, S., Montecchio, M., Pilstål, R., Su, Y., Kuruvilla, J., Elvén, M., Ziauddin, J. M. E., Anandapadamanaban, M., Cristóbal, S., Lundström, P., et al. (2015) · Structure · doi:10.1016/j.str.2015.10.010 · Cited by 62
Hu, C., Xia, H., Bai, S., Zhao, J., Edwards, H. J., Li, X., Yang, Y., Lyu, J., Wang, G., Zhan, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15281 · Cited by 61
Intravesical Instillation of c-MYC Inhibitor KSI-3716 Suppresses Orthotopic Bladder Tumor Growth
Jeong, K., Kim, K., Seo, H.-H., Shin, S.-P., Ahn, K.-O., Ji, M.-J., Park, W. S., Kim, I.-H., Lee, S.-J., & Seo, H. K. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.07.019 · Cited by 55
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
Farrington, C. C., Yuan, E., Mazhar, S., Izadmehr, S., Hurst, L., Allen-Petersen, B. L., Janghorban, M., Chung, E. M., Wolczanski, G., Galsky, M. D., et al. (2020) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)49933-9 · Cited by 53
Butler, D. S. C., Cafaro, C., Putze, J., Wan, M. L. Y., Tran, T. H., Ambite, I., Ahmadi, S., Kjellström, S., Welinder, C., Chao, S. M., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00805-3 · Cited by 52
PIAS1 Promotes Lymphomagenesis through MYC Upregulation
Rabellino, A., Melegari, M., Tompkins, V. S., Chen, W., Ness, B. G. V., Teruya‐Feldstein, J., Conacci‐Sorrell, M., Janz, S., & Scaglioni, P. P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.015 · Cited by 51
Li, Z., Lim, S. L., Tao, Y., Li, X., Xie, Y., Yang, C., Zhang, Z., Jiang, Y., Zhang, X., Cao, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574525 · Cited by 51
In vitro anticancer activity of fluphenazine, perphenazine and prochlorperazine. A review
Otręba, M., & Kośmider, L. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.4046 · Cited by 50
E3 ubiquitin ligase Mule ubiquitinates Miz1 and is required for TNFα-induced JNK activation
Yang, Y., Do, H., Tian, X., Zhang, C., Liu, X., Dada, L. A., Sznajder, J. I., & Liu, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913690107 · Cited by 49
Relationship Between myc Oncogene Activation and MHC Class I Expression
Schrier, P. I., & Peltenburg, L. T. C. (1992) · Advances in cancer research · doi:10.1016/s0065-230x(08)60826-x · Cited by 47
Jeong, K., Ahn, K.-O., & Yang, C. (2010) · Molecular BioSystems · doi:10.1039/c002534h · Cited by 46
Zhang, W., Zhang, J., Xu, C., Zhang, S., Bian, S., Jiang, F., Ni, W., Qu, L., Lu, C., Ni, R., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1109-2 · Cited by 43
Takayama, M.-A., Taira, T., Tamai, K., Iguchi‐Ariga, S. M. M., & Ariga, H. (2000) · Genes to Cells · doi:10.1046/j.1365-2443.2000.00338.x · Cited by 40
Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer
Seo, H. K., Ahn, K.-O., Jung, N.-R., Shin, J., Park, W. S., Lee, K. H., Lee, S.-J., & Jeong, K. (2014) · Oncotarget · doi:10.18632/oncotarget.1545 · Cited by 38
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
Crawford, L., Campbell, D. C., Morgan, J. J., Lawson, M. A., Down, J. M., Chauhan, D., McAvera, R. M., Morris, T. C., Hamilton, C., Krishnan, A., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1345-x · Cited by 37
Huang, S., Chen, Y., Liang, Z.-M., Li, N., Liu, Y., Zhu, Y., Liao, D., Zhou, X. Z., Lu, K. P., Yao, Y., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00322 · Cited by 36
Sin3b Interacts with Myc and Decreases Myc Levels
García‐Sanz, P., Quintanilla, A., Lafita‐Navarro, M. C., Moreno‐Bueno, G., García-Gutiérrez, L., Tabor, V., Varela, I., Shiio, Y., Larsson, L.-G., Portillo, F., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538744 · Cited by 35
Thomas, L. R., Adams, C. M., Fesik, S. W., Eischen, C. M., & Tansey, W. P. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1709388 · Cited by 35
Dhanasekaran, R., Park, J., Yevtodiyenko, A., Bellovin, D. I., Adam, S. J., Rajan, A., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.008 · Cited by 35
Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances
Conte, M., & Altucci, L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2037 · Cited by 34
A moving target: structure and disorder in pursuit of Myc inhibitors
Bayliss, R. W., Burgess, S. G., Leen, E. N., & Richards, M. W. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160328 · Cited by 34
HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP
Bhattacharya, S., & Ghosh, M. K. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0228-6 · Cited by 32
Sammak, S., Allen, M. D., Hamdani, N., Bycroft, M., & Zinzalla, G. (2018) · FEBS Journal · doi:10.1111/febs.14660 · Cited by 30
Formation of a structurally-stable conformation by the intrinsically disordered MYC:TRRAP complex
Feris, E. J., Hinds, J. W., & Cole, M. D. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225784 · Cited by 29
CDC6 interacts with c‐Myc to inhibit E‐box‐dependent transcription by abrogating c‐Myc/Max complex
Takayama, M.-A., Taira, T., Iguchi‐Ariga, S. M. M., & Ariga, H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01756-7 · Cited by 16
Chen, C.-H., Lin, D., Cheng, C.-W., Lin, C., Lo, Y.-K., Yen, C., Lee, A. Y., & Hsiao, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2204 · Cited by 12
Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism
Melo, J. D., Kim, S. S., Lourenco, C., & Penn, L. Z. (2017) · Oncogene · doi:10.1038/onc.2017.268 · Cited by 10
Cited by
Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., et al. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 369
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Guan, X., Yang, J., Wang, W., Zhao, B., Hu, S., Yu, D., Yuan, L., Shi, Y., Xu, J., Dong, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106703 · Cited by 33
Beaulieu, M.-E., Martínez-Martín, S., Kaur, J., Castillo Cano, V., Massó-Vallés, D., Foradada Felip, L., López-Estévez, S., Serrano del Pozo, E., Thabussot, H., & Soucek, L. (2023) · Cancers · doi:10.3390/cancers15030826 · Cited by 12
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Metadata
- Authors
- Llombart, V., & Mansour, M. R.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 75
- Pages
- 103756
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W4200543380
- Cited by
- 472
- References
- 151
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.